PROJECT SUMMARY South Rampart Pharma (SRP) is an early clinical-stage company focused on developing SRP-001, a novel non-opioid designed to treat moderate-to-severe acute and chronic pain without the dose-limiting hepatotoxicity of acetaminophen and nephrotoxicity of NSAIDs, and the misuse and addictive potential of opioids. SRP-001 is currently in Phase 1 trials where interim data support the expectation of safety and acceptable bioavailability and pharmacokinetics. SRP is currently conducting a Series A round to fund a planned Phase 2 scheduled to begin in H2 2023. Further development of SRP-001 will require third-party investor support to deliver proof-of-concept efficacy data in a Phase 2 trial. This will be followed by a critical need to partner with a major pharmaceutical or consumer health company to complete pivotal Phase 3 trials and commercialization. Based on historical data for pain therapeutics trials, the estimated cost of a Phase 3 program is $150M—a figure that is not attainable without a strategic partnership. In this Commercial Readiness Project submitted to PAR-23-069 (HEAL Commercialization Readiness (CRP) Program: Embedded Entrepreneurs for Small Business in Pain Management), SRP proposes to hire a CFO at 50% effort to pursue an aggressive partner engagement plan to secure a partnership to support Phase 3 trials and commercialization. SRP proposes two aligned aims with the two required activities outlined by PAR-23-069: Aim 1. Hire a business development expert in a company leadership role at 50% effort. Expected Outcome: 1. CFO hired for 50% effort by month 2 of the project. Aim 2. Execute a partnering plan. Expected Outcomes: 1. Initial contact with 200-300 prospective investors and potential partners with a specific interest in pain and CNS innovation by the end of Year 1. 2. Meetings with 50-75 interested prospects by the end of Year 1. 3. Data room access granted to 20-30 prospects interested in further discussions. 4. Additional meetings with the prospect’s broader team and negotiations with 10-15 prospects through Year 2. 5. Agreements secured with 2-5 lead investors, closing out Series A financing by Month 18, and securing a partnership agreement with a major pharmaceutical company by the end of Year 2.

PROJECT NARRATIVE Current treatments for acute and chronic pain have a high potential for misuse and addiction (i.e., opioids) or have a considerable risk of liver toxicity (i.e., acetaminophen) or kidney toxicity (i.e., NSAIDs such as ibuprofen and aspirin) with intentional or unintentional overdose. This project seeks to advance the development of SRP- 001, a safe non-opioid treatment for moderate-to-severe acute and chronic pain, by hiring a business development executive to secure a product development partnership with a major pharmaceutical company to complete testing and commercial development. Commercialization of SRP-001 is expected to provide doctors and patients with a new safe, effective, non-addictive treatment option for moderate-to-severe acute and chronic pain across a broad array of indications.